Related Experiment Videos
Comprehensive review: neuromuscular blocking agents in critical care
Critical Care Nursing Quarterly
|August 1, 1995
Summary
Neuromuscular blocking agents (NMBAs) use in ICUs is controversial due to adverse effects and lack of evidence. Safer, effective use requires strict patient selection, monitoring, and early discontinuation of pharmacologic paralysis.
Area of Science:
- Critical Care Medicine
- Pharmacology
Background:
- The use of neuromuscular blocking agents (NMBAs) in intensive care units (ICUs) is widespread but controversial.
- Concerns include adverse effects like prolonged paralysis, inadequate sedation, and insufficient monitoring.
Purpose of the Study:
- To highlight controversies surrounding NMBA use in critical care.
- To emphasize the need for research to establish optimal practices and protocols for safe and effective NMBA administration.
Main Methods:
- Review of current practices and existing literature on NMBA use in critical care.
- Identification of areas of controversy and associated risks.
Main Results:
- Increased NMBA use lacks defined indications and research support, leading to complications.
- Key issues include adverse effects, knowledge gaps among professionals, inadequate concurrent sedation/analgesia, and poor monitoring.
Conclusions:
- Pharmacologic paralysis should be reserved for select patients with careful evaluation and discontinued promptly.
- Judicious use, multidisciplinary collaboration, and adverse effect prevention are crucial for safe and effective NMBA therapy, minimizing costs and suffering.